| Name | Title | Contact Details |
|---|
Founded in 1982 by David W. Mortara, PhD, Mortara Instrument was born with a guiding philosophy: design to a need, keep it simple, and make it economically accessible. Building on this philosophy, Mortara Instrument has created a complete line of
ITH Healthcare is a Forest Hills, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Arriva Medical is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Based at NASA-Ames Research Center, Scanadu is using mobile and sensor technology to develop a portfolio of FDA approved, consumer friendly products that put the experience of an emergency room in the palm of your hand. Unveiled in November 2012, the company is working to ensure this is the last generation to know so little about our health. The product portfolio includes the Scanadu Scout vital sign monitor and Scanadu Urine, a urine analysis test. In July 2013, Scanadu became the most funded campaign on Indiegogo, enlisting supporters to be a part of the first usability study, followed by clinical studies for the company’s road to FDA approval.
NeuroOne Medical Technologies Incorporated (Ticker: NMTC) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, initially targeting epilepsy. Today, our attention is on the development and commercialization of patented thin-film, cortical electrode technology for intracranial electroencephalography (iEEG) and depth electrodes for stereoelectroencephalography (sEEG) recording of brain activity. The products currently available in these categories have significant limitations such as low recording resolution and high risk of infection. NeuroOne believes our technology can address these unmet needs upon initial commercialization with pipeline technology to advance the field by enabling minimally invasive techniques and all-in-one diagnostic and therapeutic options. While our initial focus is Epilepsy, future applications in Parkinson`s disease, Essential tremors, and Dystonia are within sight. NeuroOne technologies will be presented to a well-defined market, eager for the advancement they bring. There are 188 hospital centers licensed to perform epilepsy surgical procedures in the U.S. The current addressable market opportunity for is approximately $525.6 million. As more patients choose the minimally invasive procedures made available by NeuroOne technology, the future opportunity is estimated to be approximately $14.9 billion with full market penetration.